US2002136723A1PendingUtilityA1

Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease

53
Assignee: KENNEDY INST OF RHEUMATOLOGYPriority: Oct 6, 1992Filed: Aug 3, 2001Published: Sep 26, 2002
Est. expiryOct 6, 2012(expired)· nominal 20-yr term from priority
Inventors:Marc FeldmannRavinder N. Maini
A61P 37/00A61P 37/06A61P 29/00A61K 38/1793A61K 31/519A61K 39/3955A61K 2039/505A61K 39/395A61P 1/00A61K 31/505C07K 16/241A61K 45/06A61P 19/02A61K 2039/545C07K 2317/24A61K 39/39541C07K 2319/00
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.

Claims

exact text as granted — not AI-modified
What is claimed:  
     
         1 . A method for treating or preventing a tumor necrosis factor-mediated disease in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor antibody or fragment thereof to the individual, in therapeutically effective amounts.  
     
     
         2 . A method of  claim 1  wherein the anti-tumor necrosis factor antibody and methotrexate are administered simultaneously.  
     
     
         3 . A method of  claim 1  wherein the anti-tumor necrosis factor antibody and methotrexate are administered sequentially.  
     
     
         4 . A method of  claim 1  wherein the tumor necrosis factor-mediated disease is selected from the group consisting of: autoimmune disease, acute or chronic immune disease, inflammatory disease and neurodegenerative disease.  
     
     
         5 . A method of  claim 4  wherein the anti-tumor necrosis factor antibody is administered in multiple doses.  
     
     
         6 . A method of  claim 5  wherein the anti-tumor necrosis factor antibody is a chimeric antibody.  
     
     
         7 . A method of  claim 6  wherein the chimeric antibody binds to one or more amino acids of hTNFα selected from the group consisting of about 87-108 and about 59-80.  
     
     
         8 . A method of  claim 6  wherein the chimeric antibody binds to the epitope of cA2.  
     
     
         9 . A method of  claim 8  wherein the chimeric antibody is cA2.  
     
     
         10 . A method for treating or preventing rheumatoid arthritis in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor antibody to the individual, in therapeutically effective amounts.  
     
     
         11 . A method of  claim 10  wherein the anti-tumor necrosis factor antibody and methotrexate are administered simultaneously.  
     
     
         12 . A method of  claim 10  wherein the anti-tumor necrosis factor antibody and methotrexate are administered sequentially.  
     
     
         13 . A method of  claim 10  wherein the anti-tumor necrosis factor antibody is administered in multiple doses.  
     
     
         14 . A method of  claim 13  wherein the anti-tumor necrosis factor antibody is a chimeric antibody.  
     
     
         15 . A method of  claim 14  wherein the chimeric antibody binds to one or more amino acids of hTNFα selected from the group consisting of about 87-108 and about 59-80.  
     
     
         16 . A method of  claim 14  wherein the chimeric antibody binds to the epitope of cA2.  
     
     
         17 . A method of  claim 16  wherein the chimeric antibody is cA2.  
     
     
         18 . A method for treating or preventing Crohn's disease in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor antibody to the individual, in therapeutically effective amounts.  
     
     
         19 . A method of  claim 18  wherein the anti-tumor necrosis factor antibody and methotrexate are administered simultaneously.  
     
     
         20 . A method of  claim 18  wherein the anti-tumor necrosis factor antibody and methotrexate are administered sequentially.  
     
     
         21 . A method of  claim 18  wherein the anti-tumor necrosis factor antibody is administered in multiple doses.  
     
     
         22 . A method of  claim 21  wherein the anti-tumor necrosis factor antibody is a chimeric antibody.  
     
     
         23 . A method of  claim 22  wherein the chimeric antibody binds to one or more amino acids of hTNFα selected from the group consisting of about 87-108 and about 59-80.  
     
     
         24 . A method of  claim 22  wherein the chimeric antibody binds to the epitope of cA2.  
     
     
         25 . A method of  claim 22  wherein the chimeric antibody is cA2.  
     
     
         26 . A composition comprising methotrexate and an anti-tumor necrosis factor antibody or fragment thereof.  
     
     
         27 . A composition of  claim 26  wherein the anti-tumor necrosis factor antibody is a chimeric antibody.  
     
     
         28 . A composition of  claim 27  wherein the chimeric antibody binds to one or more amino acids of hTNFÁ selected from the group consisting of about 87-108 and about 59-80.  
     
     
         29 . A composition of  claim 27  wherein the chimeric antibody binds to the epitope of cA2.  
     
     
         30 . A composition of  claim 29  wherein the chimeric antibody is cA2.  
     
     
         31 . A method for treating or preventing a tumor necrosis factor-mediated disease in an individual in need thereof comprising co-administering methotrexate and a tumor necrosis factor antagonist to the individual, in therapeutically effective amounts.

Join the waitlist — get patent alerts

Track US2002136723A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.